Driving sustainable healthcare solutions for everyone affected by cancer
We imagine a world in which patients are always at the heart of cancer care
About us
All.Can is an international multi-stakeholder not-for-profit organisation working to improve the efficiency of cancer care by focusing on what matters to patients.
We believe the most effective way to create change is to give everyone a seat at the table. All.Can international’s membership therefore includes representatives from patient organisations, policymakers, healthcare professionals, research and industry.
What we do
All.Can aims to identify inefficiencies in cancer care, which we define as anything that doesn't focus on what matters to patients. Through research and collaboration, we highlight best practices and develop policy recommendations to improve cancer care for all.
All.Can patient survey
All.Can defines inefficiency in cancer care as anything that does not focus on what matters to patients – so we asked patients for their unique perspective.
Collaboration with iPAAC
All.Can is proud to be a collaborating partner in the Innovative Partnership for Action Against Cancer (iPAAC), a joint action of the European Commission.
Efficiency hub
All.Can is gathering examples of best practice in cancer care from around the world to create a learning community and help organisations find and implement potential solutions to common issues.
Latest publication
All.Can at 3
The annual report of All.Can’s third year showcases the initiative’s achievements and milestones, with a particular focus on the work of the All.Can national initiatives, and looks ahead to what comes next.
Latest blog
Patient story: ‘The fact my cancer was missed feels like a failure’
This patient story describes a delay in receiving a diagnosis and struggling with the intense chemotherapy.
Latest news
All.Can Media Coverage – Korea Biomedical Review
‘Efficient cancer care meeting highest patient needs produce best treatment results’ Read the article and interview (link here) with All.Can CEO Eduardo Pisani that was published on 15 January 2021 in the Korea Biomedical Review in light of the recent launch of the All.Can National…